Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction : A Prospective Pilot Study
© 2023 American Academy of Otolaryngology-Head and Neck Surgery Foundation..
OBJECTIVE: The objective of this study was to explore the safety and feasibility of stellate ganglion blocks (SGBs) to treat persistent COVID-19-induced olfactory dysfunction (OD). Secondarily, the goal was to determine effect sizes to plan a future randomized clinical trial.
STUDY DESIGN: Prospective case series.
SETTING: Quaternary Care Academic Medical Center.
METHODS: In this single-arm pilot trial, adult participants with a COVID-19 diagnosis ≥ 12 months prior to enrollment with OD underwent bilateral SGBs. Subjects were followed for 1 month after completion of SGB. The primary outcome measure was the change in the Clinical Global Impression-Improvement Scale for smell loss. Secondary outcome measures included changes in the University of Pennsylvania Smell Identification Test (UPSIT) and Olfactory Dysfunction Outcomes Rating (ODOR).
RESULTS: Twenty participants were enrolled with a mean (SD) age of 46 (11) years and a mean (SD) duration of OD of 21 (5) months. At 1 month, 10 (50%) participants experienced at least slight subjective improvement in their OD, 11 (55%) attained a clinically meaningful improvement in smell identification using the UPSIT, and 7 (35%) achieved a clinically meaningful improvement in olfactory-specific quality of life (QoL) measured by the ODOR. The median difference between UPSIT scores at baseline and 1 month was 6 (95% confidence interval: 3-11), exceeding the minimal clinically important difference of 4. There were no serious adverse events.
CONCLUSION: Sequential SGBs for COVID-19-associated OD were safe and associated with modest improvements in subjective olfaction, odor identification, and olfactory-specific QoL. A placebo-controlled trial is warranted to determine the efficacy of SGBs for COVID-19-associated OD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:170 |
|---|---|
| Enthalten in: |
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery - 170(2024), 1 vom: 25. Jan., Seite 272-276 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peterson, Andrew M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anosmia |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 07.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ohn.530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362466009 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362466009 | ||
| 003 | DE-627 | ||
| 005 | 20240207232044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ohn.530 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM362466009 | ||
| 035 | |a (NLM)37750244 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peterson, Andrew M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction |b A Prospective Pilot Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 American Academy of Otolaryngology-Head and Neck Surgery Foundation. | ||
| 520 | |a OBJECTIVE: The objective of this study was to explore the safety and feasibility of stellate ganglion blocks (SGBs) to treat persistent COVID-19-induced olfactory dysfunction (OD). Secondarily, the goal was to determine effect sizes to plan a future randomized clinical trial | ||
| 520 | |a STUDY DESIGN: Prospective case series | ||
| 520 | |a SETTING: Quaternary Care Academic Medical Center | ||
| 520 | |a METHODS: In this single-arm pilot trial, adult participants with a COVID-19 diagnosis ≥ 12 months prior to enrollment with OD underwent bilateral SGBs. Subjects were followed for 1 month after completion of SGB. The primary outcome measure was the change in the Clinical Global Impression-Improvement Scale for smell loss. Secondary outcome measures included changes in the University of Pennsylvania Smell Identification Test (UPSIT) and Olfactory Dysfunction Outcomes Rating (ODOR) | ||
| 520 | |a RESULTS: Twenty participants were enrolled with a mean (SD) age of 46 (11) years and a mean (SD) duration of OD of 21 (5) months. At 1 month, 10 (50%) participants experienced at least slight subjective improvement in their OD, 11 (55%) attained a clinically meaningful improvement in smell identification using the UPSIT, and 7 (35%) achieved a clinically meaningful improvement in olfactory-specific quality of life (QoL) measured by the ODOR. The median difference between UPSIT scores at baseline and 1 month was 6 (95% confidence interval: 3-11), exceeding the minimal clinically important difference of 4. There were no serious adverse events | ||
| 520 | |a CONCLUSION: Sequential SGBs for COVID-19-associated OD were safe and associated with modest improvements in subjective olfaction, odor identification, and olfactory-specific QoL. A placebo-controlled trial is warranted to determine the efficacy of SGBs for COVID-19-associated OD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anosmia | |
| 650 | 4 | |a hyposmia | |
| 650 | 4 | |a olfaction | |
| 650 | 4 | |a stellate ganglion | |
| 700 | 1 | |a Miller, Brevin J |e verfasserin |4 aut | |
| 700 | 1 | |a Kallogjeri, Dorina |e verfasserin |4 aut | |
| 700 | 1 | |a Piccirillo, Jay F |e verfasserin |4 aut | |
| 700 | 1 | |a Kukuljan, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Roland, Lauren T |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Crock, Lara W |e verfasserin |4 aut | |
| 700 | 1 | |a Farrell, Nyssa F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery |d 1982 |g 170(2024), 1 vom: 25. Jan., Seite 272-276 |w (DE-627)NLM012595721 |x 1097-6817 |7 nnns |
| 773 | 1 | 8 | |g volume:170 |g year:2024 |g number:1 |g day:25 |g month:01 |g pages:272-276 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ohn.530 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 170 |j 2024 |e 1 |b 25 |c 01 |h 272-276 | ||